Breaking News

FDA Gives First Approval to Pre-Surgical Breast Cancer Drug
Download PDF
1 Star2 Stars3 Stars4 Stars5 Stars (No Ratings Yet)
Loading...

On Monday, the FDA gave its first approval to a pre-surgical breast cancer drug. The drug, Perjeta, manufactured by Roche had been previously approved for late-stage breast cancer last year. Accelerated approval of the drug for treating pre-surgical breast cancer was given following a recent study that showed women who received the drug as an initial treatment were more likely to be free of cancer within 12 weeks earlier than those receiving prevalent drug combinations for treating breast cancer.

In early September, FDA scientists had positively reviewed the drug a few days before a panel of independent cancer specialists reviewed the benefits of Perjeta against risks of its use. The external panel voted 13-0 and the panel chairman, Dr. Mikkal Sekeres called the vote “a historic moment.”

  
What
Where


Earlier in September, CBS News contributor Dr. David Agus, of the Westside Cancer Center at the University of Southern California said on CBS This Morning that Perjeta was “an exciting drug because it targets a particular pathway in the cancer – an ‘on’ switch if you will. About 15,000 women a year have this very aggressive cancer with … (a molecule called HER-2) and it turns it off.”

The FDA based its approval on a 417-woman study that compared Perjeta in different combinations against prevalent drug combinations for breast cancer. When combined with Herceptin and standard chemotherapy, the cancer went down to undetectable levels in 39 percent of the women.

Perjeta is not a blanket treatment for all kinds of breast cancer, but is targeted towards breast cancer that is triggered by the protein HER-2.

Get JD Journal in Your Mail

Subscribe to our FREE daily news alerts and get the latest updates on the most happening events in the legal, business, and celebrity world. You also get your daily dose of humor and entertainment!!




Dr. Richard Pazdur, the director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research, after approving Perjeta for pre-surgical breast cancer treatment, said, “We are seeing a significant shift in the treatment paradigm for early stage breast cancer … By making effective therapies available to high-risk patients in the earliest disease setting, we may delay or prevent cancer recurrences.”





 

RELEVANT JOBS

DEPUTY STAFF COUNSEL / ATTORNEY

USA-CA-Auburn

JOIN OUR OUTSTANDING TEAM OF PROFESSIONALS! DEPUTY STAFF COUNSEL / ATTORNEY $129,615 - $165,42...

Apply now

Associate Attorney

USA-CA-Rohnert Park

Zimmerman Pavone LLP is looking for an attorney admitted to practice in California who is inter...

Apply now

Labor & Employment Partner in Houston, Austin or Dallas (Work From Home)

USA-TX-Houston

Culhane Meadows PLLC, one of the largest non-traditional distributed law firms in the country, ...

Apply now

Labor & Employment Group partner in Dallas, Austin or Houston (Work From Home)

USA-TX-Dallas

Culhane Meadows PLLC, one of the largest non-traditional distributed law firms in the country, is...

Apply now

BCG FEATURED JOB

Locations:

Keyword:



Search Now

Personal Injury Litigator

USA-VA-Fairfax

Northern Virginia office of our client is seeking a personal injury litigator with 4+ years of stron...

Apply Now

Associate Attorney

USA-CA-Larkspur

Larkspur office of our client seeks an associate attorney with 4-6 years of experience/background pr...

Apply Now

Associate Attorney

USA-MI-Bloomfield Hills

Bloomfield Hills office of a BCG Attorney Search Top Ranked Law Firm seeks an associate attorney wit...

Apply Now

SEARCH IN ARCHIVE

To Top